Prevention of infective endocarditis

2023 ESC Guidelines for the management of endocarditis

On Behalf of the Task Force for the 2023 Infective Endocarditis Guidelines

Stefano Caselli, MD, PhD, FESC

25 August 2023



Declaration of interest

- Consulting/Royalties/Owner/ Stockholder of a healthcare company: Proctor for Abbott medical

Epidemiology

Rare condition but a major public health challenge

Incidence: 13.8 / 100.000 / Year

Mortality: 0.9 / 100.000 / Year




• 1,723,590 Disability Adjusted Life Years in 2019

Pathophysiology

Portal of Entry of the Pathogens:

- Oral cavity
- Infections of the skin
- Direct inoculation
- Healthcare exposure




Chapter 3 on prevention of endocarditis.

• 3.2 Population at Risk of infective Endocarditis

• 3.3 Situation and procedures at Risk

• 3.4 Patient's Education



Population at Risk



CLINICAL RESEARCH Prevention and epidemiology


Quantifying infective endocarditis risk in patients with predisposing cardiac conditions

Martin H. Thornhill^{1,2}°, Simon Jones^{2,4}, Bernard Prendergast⁵, Larry M. Baddour⁶, John B. Chambers⁵, Peter B. Lockhart², and Mark J. Dayer⁷

Reference incidence of IE in UK 3.6/100,000/year

Intermediate Risk: 280/100,000/year

High Risk: 497/100,000/year



High Risk Patients



- 1. Patients with previous IE
- 2. Patients with prosthetic valves
- 3. CHD: untreated cyanotic or those treated with postoperative palliative shunts, conduits or other prostheses
- 4. Patients with VAD as destination therapy

Intermediate Risk Patients



- 1. Rheumatic heart disease
- 2. Non-rheumatic degenerative valve disease
- 3. Congenital valve abnormalities
- 4. Cardiovascular implanted electronic devices
- 5. Hypertrophic cardiomyopathy

Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk for IE (1)

| Recommendations | Class | Level | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|
| General prevention measures are recommended in individuals at high and intermediate risk for IE. | 1 | C | New |
| Antibiotic prophylaxis is recommended in patients with previous IE. | 1 | В | Revised |
| Antibiotic prophylaxis is recommended in patients with surgically implanted prosthetic valves and with any material used for surgical cardiac valve repair. | ı | С | Revised |
| Antibiotic prophylaxis is recommended in patients with transcatheter implanted aortic and pulmonary valvular prostheses. | ı | С | Revised |
| Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure. | | С | Revised |

Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk for IE (2)

| Recommendations | Class | Level | | |
|---------------------------------------------------------------------------------------------------------------|-------|-------|--------|------|
| Antibiotic prophylaxis is recommended in patients with ventricular assist devices. | 1 | C 🖥 | New | |
| Antibiotic prophylaxis should be considered in patients with transcatheter mitral and tricuspid valve repair. | lla | C | Revise | ed . |
| Antibiotic prophylaxis may be considered in recipients of heart transplant. | IIb | C - | New | * |
| Antibiotic prophylaxis is not recommended in other patients at low risk for IE. | Ш | С | | |

Prevention measures

Patients should be encouraged to maintain twice daily tooth cleaning and to seek professional dental cleaning and follow-up at least twice yearly for high-risk patients and yearly for others Strict cutaneous hygiene, including optimized treatment of chronic skin conditions

Disinfection of wounds

Curative antibiotics for any focus of bacterial infection

No self-medication with antibiotics

Strict infection control measures for any at-risk procedure

Discouragement of piercing and tattooing

Limitation of infusion catheters and invasive procedures when possible. Strict adherence to care bundles for central and peripheral cannulae should be performed













Prophylactic antibiotic regime for high-risk dental procedures

| Situation | Antibiotic | Single-dose 30-60 m | nin before procedure |
|--------------------------|--------------------------------|---------------------|------------------------------------------------|
| Situation | Antibiotic | Adults | Children |
| No allergy to | Amoxicillin | 2 g orally | 50 mg/kg orally |
| penicillin or | Ampicillin | 2 g i.m. or i.v. | 50 mg/kg i.v. or i.m. |
| ampicillin | Cefazolin or ceftriaxone | 1 g i.m. or i.v. | 50 mg/kg i.v. or i.m. |
| Allergy to | Cephalexin | 2 g orally | 50 mg/kg orally |
| penicillin or ampicillin | Azithromycin or clarithromycin | 500 mg orally | 15 mg/kg orally |
| umpiemm | Doxycycline | 100 mg orally | <45 kg, 2.2 mg/kg orally >45 kg, 100 mg orally |
| | Cefazolin or ceftriaxone | 1 g i.m. or i.v. | 50 mg/kg i.v. or i.m. |

Procedures at Risk

1. Dental procedures



2. Non-dental procedures



3. Cardiac procedures



Dental Procedures



- Case-crossover Study in almost 8million US subjects.
- Invasive dental procedures significantly associated with the incidence of endocarditis.
- Antibiotic-prophylaxis before invasive dental procedures was associated with reduced incidence of Endocardits.


ORIGINAL INVESTIGATIONS

Antibiotic Prophylaxis Against Infective Endocarditis Before Invasive Dental Procedures



Martin H. Thornhill, MBBS, BDS, PhD, a.b. Teresa B. Gibson, PhD, Frank Yoon, PhD, Mark J. Dayer, MBBS, PhD, d Bernard D. Prendergast, BM, BS, DM, Peter B. Lockhart, DDS, Patrick T. O'Gara, MD, Larry M. Baddour, MD

■ Without Antibiotic Prophylaxis ■ With Antibiotic Prophylaxis



©ESC

Non-Dental Procedures




JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0 3018 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELDEVIER VOL. 71, NO. 24, 2018

Invasive Procedures Associated With the Development of Infective Endocarditis



Imre Janszky, MD, PnD, ^{n,b} Katalin Gémes, PnD, ^c Staffan Ahnve, MD, PnD, ^c Hilmir Asgeirsson, MD, PnD, ^{d,a}
Jette Möller, PnD^c


CENTRAL ILLUSTRATION Relative Risks for Infective Endocarditis After Selected Procedures: Logarithmic Scale



Original research

Temporal association between invasive procedures and infective endocarditis

Martin H Thornhill , 1,2 Annabel Crum, Richard Campbell, Tony Stone, Ellen C Lee, Mike Bradburn, Veronica Fibisan, Mark Dayer , 5
Bernard D Prendergast , Feter Lockhart, Larry Baddour , Jon Nicoll



Recommendations for infective endocarditis prevention in high-risk patients

| Recommendations | Class | Level | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|----|
| Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the gingival or periapical region of the teeth. | 1 | В | Revis | ed |
| Systemic antibiotic prophylaxis may be considered for high-risk patients undergoing an invasive diagnostic or therapeutic procedure of the respiratory, gastrointestinal, genitourinary tract, skin, or musculoskeletal systems. | IIb | C 7 | New | |

Cardiac Procedures



| Recommendations | Class | Level | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-----|---|
| Pre-operative screening for nasal carriage of <i>S. aureus</i> is recommended before elective cardiac surgery or transcatheter valve implantation to treat carriers. | 1 | Α | | |
| Peri-operative antibiotic prophylaxis is recommended before placement of a CIED. | 1 | Α | | , |
| Optimal pre-procedural aseptic measures of the site of implantation is recommended to prevent CIED infections. | 1 | В | New | 1 |
| Periprocedural antibiotic prophylaxis is recommended in patients undergoing surgical or transcatheter implantation of a prosthetic valve, intravascular prosthetic, or other foreign material. | 1 | В | | |
| Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization laboratory environment. | ı | c 🖥 | New | * |


Cardiac Procedures (cont.)

| Recommendations | Class | Level | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|----|
| Elimination of potential sources of sepsis (including of dental origin) should be considered ≥2 weeks before implantation of a prosthetic valve or other intracardiac or intravascular foreign material, except in urgent procedures. | lla | С | |
| Antibiotic prophylaxis covering for common skin flora including <i>Enterococcus</i> spp. and <i>S. aureus</i> should be considered before TAVI and other transcatheter valvular procedures. | lla | c 🖥 | Ne |
| Systematic skin or nasal decolonization without screening for <i>S. aureus</i> is not recommended. | Ш | С | |

3.4 Patient's Education

Patients should be educated on the risks of endocarditis and on its prevention

National cardiac societies are invited to develop specific Patient's cards.



Thank you!

On Behalf of the Task Force for the 2023 Infective Endocarditis Guidelines

Stefano Caselli, MD, PhD, FESC

25 Aug 2023



Clinical Practice Guidelines Webinar SEPTEMBER 2023 on ESC365



甘 15 September 2023 18:00 CEST



REGISTER TO ACCESS

What's the latest on infective endocarditis. ESC 2023 Clinical Practice Guidelines - Webinar Series

WEBINAR



See details →



甘 27 September 2023 18:00 CEST



REGISTER TO ACCESS

Diagnostic challenges in infective endocarditis. ESC 2023 Clinical Practice Guidelines - Webinar Series

WEBINAR



See details →

